Study Summary
This trial will investigate how dopamine affects the disconnect between pain caused by a stimulus and the pain felt, with the aim of understanding chronic pain better.
- Pain
Treatment Effectiveness
Effectiveness Progress
Study Objectives
4 Primary · 0 Secondary · Reporting Duration: 6 months
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Methylphenidate
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
30 Total Participants · 2 Treatment Groups
Primary Treatment: Methylphenidate · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 65 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does this medical experiment accept enrollees aged 45 and up?
"This clinical study is in search of participants that are over 18 years old and below 65." - Anonymous Online Contributor
Who meets the specified criteria to participate in this clinical experiment?
"To qualify for this research project, applicants must experience pain and be between 18 to 65 years of age. The team is aiming to recruit around 30 participants in total." - Anonymous Online Contributor
Has the Federal Drug Administration approved Methylphenidate for use?
"Our team at Power assigned Methylphenidate a safety score of 2, as this is a Phase 2 trial and while there are some data points attesting to its safety, none have yet been collected which support its efficacy." - Anonymous Online Contributor
Is recruitment for this trial still open?
"Clinicaltrials.gov records assert that this medical investigation is in search of participants, with the original post being made on September 19th 2022 and updated most recently on December 30th 2022." - Anonymous Online Contributor
How many individuals are being studied as part of this medical investigation?
"Affirmative, the info hosted on clinicaltrials.gov shows that this medical study is actively looking for subjects to join. This trial was first published on September 19th 2022 and has been latest revised at December 30th of the same year. The researchers are aiming to enrol a total of thirty individuals across one location." - Anonymous Online Contributor